

# Joachim Ficker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5829710/publications.pdf>

Version: 2024-02-01

117  
papers

6,270  
citations

117571

34  
h-index

69214

77  
g-index

170  
all docs

170  
docs citations

170  
times ranked

4834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. <i>Scientific Reports</i> , 2022, 12, 1435.	1.6	8
2	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e351-e361.	2.2	24
3	Specialized Biopsychosocial Care in Inpatient Somatic Medicine Units—A Pilot Study. <i>Frontiers in Public Health</i> , 2022, 10, 844874.	1.3	1
4	Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis. <i>Mycoses</i> , 2022, 65, 747-752.	1.8	20
5	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	3.1	17
6	Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110123.	1.4	8
7	Beyond the AHI—pulse wave analysis during sleep for recognition of cardiovascular risk in sleep apnea patients. <i>Journal of Sleep Research</i> , 2021, 30, e13364.	1.7	13
8	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 476-486.	5.2	254
9	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021, 10, 3093-3105.	1.3	23
10	Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial. <i>Respiration</i> , 2021, 100, 1174-1185.	1.2	6
11	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , the, 2021, 8, e627-e636.	2.2	11
12	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. <i>International Journal of COPD</i> , 2021, Volume 16, 3189-3199.	0.9	5
13	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 4106-4119.	1.3	4
14	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	1.0	106
15	Bridging Whole-Lung Lavage with Venovenous Extracorporeal Life Support for Pulmonary Alveolar Proteinosis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1115-1117.	0.6	5
16	Gluteal abscess caused by <i>Mycobacterium tuberculosis</i> . <i>Techniques in Coloproctology</i> , 2020, 24, 1315-1316.	0.8	0
17	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2020, 20, 1185.	1.1	75
18	Low long-term mortality in patients with sleep apnoea and positive airway pressure therapy: analysis of a large German healthcare database. <i>Somnologie</i> , 2020, 24, 151-158.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095135.	0.6	24
20	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. <i>Cancers</i> , 2020, 12, 2319.	1.7	52
21	Improving Contrast Enhancement in Pulmonary CTA: The value of breathing maneuvers. <i>European Journal of Radiology Open</i> , 2020, 7, 100280.	0.7	3
22	&lt;p&gt;Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort&lt;/p&gt;. Patient Preference and Adherence, 2019, Volume 13, 1711-1721.	0.8	10
23	CAT score single item analysis in patients with COPD: Results from COSYCONET. <i>Respiratory Medicine</i> , 2019, 159, 105810.	1.3	16
24	Complete Cast of the Bronchial Tree. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2019, 116, 318.	0.6	0
25	Diagnosis and management of $\alpha$ 1-antitrypsin deficiency in Europe: an expert survey. <i>ERJ Open Research</i> , 2019, 5, 00171-2018.	1.1	36
26	Cervical Emphysema in Boerhaave Syndrome. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2019, 116, 211.	0.6	2
27	Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 123-129.	1.1	12
28	Effect of a patient engagement tool on positive airway pressure adherence: analysis of a German healthcare provider database. <i>Sleep Medicine</i> , 2018, 41, 20-26.	0.8	39
29	Predictors of positive airway pressure therapy termination in the first year: analysis of big data from a German homecare provider. <i>BMC Pulmonary Medicine</i> , 2018, 18, 186.	0.8	17
30	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study. <i>BMC Cancer</i> , 2018, 18, 333.	1.1	10
31	Medical Treatment of COPD. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2018, 155, 599-605.	0.6	17
32	Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2017, 189, 423-430.	0.7	18
33	Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 19-33.	1.1	20
34	Long-term efficacy and safety of $\alpha$ 1 proteinase inhibitor treatment for emphysema caused by severe $\alpha$ 1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). <i>Lancet Respiratory Medicine</i> , 2017, 5, 51-60.	5.2	151
35	Dyspnea following intravenous drug use. <i>Respiratory Medicine Case Reports</i> , 2017, 20, 192-194.	0.2	1
36	REM Sleep Imposes a Vascular Load in COPD Patients Independent of Sleep Apnea. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 565-572.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Telemedicine-based proactive patient management during positive airway pressure therapy. <i>Somnologie</i> , 2017, 21, 121-127.	0.9	34
38	Obstructive sleep apnea (OSA) and clinical depression prevalence in a sleep center. <i>Sleep and Breathing</i> , 2017, 21, 311-318.	0.9	33
39	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2425-2434.	1.8	9
40	German S3 Guideline Nonrestorative Sleep/Sleep Disorders, chapter "Sleep-Related Breathing Disorders in Adults," short version. <i>Somnologie</i> , 2017, 21, 290-301.	0.9	72
41	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. <i>PLoS ONE</i> , 2017, 12, e0177501.	1.1	37
42	Physician perspectives: barriers to diagnosing and treating severe AATD. , 2017, , .		0
43	Pulse wave analysis but not polysomnography recognizes sleep apnoea patients with increased cardiovascular risk. , 2017, , .		0
44	Association between change in positive airway pressure (PAP) mask type and therapy compliance. , 2017, , .		0
45	Late Breaking Abstract - Bronchoscopic Thermal Vapor Ablation (BTVA) Outcomes at 12 months in Emphysema Patients with Severe Hyperinflation, a STEP-UP RCT Subgroup Analysis. , 2017, , .		0
46	Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. , 2017, , .		1
47	Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 6771-6778.	0.5	20
48	Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. <i>Lung Cancer</i> , 2016, 95, 35-38.	0.9	31
49	Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1073-1082.	2.5	250
50	CMR imaging for follow up of isolated cardiac sarcoidosis with extensive biventricular involvement. <i>International Journal of Cardiology</i> , 2016, 221, 777-779.	0.8	3
51	Parameters of Overnight Pulse Wave under Treatment in Obstructive Sleep Apnea. <i>Respiration</i> , 2016, 92, 136-143.	1.2	5
52	Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results. <i>Lancet Respiratory Medicine</i> , 2016, 4, e44-e45.	5.2	41
53	Vascular stiffness determined from a nocturnal digital pulse wave signal. <i>Journal of Hypertension</i> , 2016, 34, 2427-2433.	0.3	9
54	Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 185-193.	5.2	130

#	ARTICLE	IF	CITATIONS
55	Detection of cardiovascular risk from a photoplethysmographic signal using a matching pursuit algorithm. <i>Medical and Biological Engineering and Computing</i> , 2016, 54, 1111-1121.	1.6	25
56	Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies – A Novel Stepwise Approach by Evaluation of Medication. <i>PLoS ONE</i> , 2016, 11, e0163408.	1.1	40
57	Prognostic value of immune response gene expression in early stage curatively resected NSCLC: Data from the JBR.10 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8528-8528.	0.8	0
58	Systematic analysis of self-reported comorbidities in the COSYCONET COPD cohort study by stepwise evaluation of medication. , 2016, , .		0
59	Targeted segmental volume reduction with vapor ablation in emphysema results in reduced RV and clinically meaningful improvement (CMI) in FEV1. , 2016, , .		0
60	Segmental lung volume reduction (LVR) with vapor better targets disease heterogeneity as compared to lobar LVR. , 2016, , .		0
61	Volume changes after segmental vapor ablation and associated improvements in FEV <sub>1</sub> . , 2016, , .		0
62	STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results. , 2016, , .		0
63	The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. <i>International Journal of Oncology</i> , 2015, 47, 963-970.	1.4	22
64	Delays in the diagnosis and treatment of women with lung cancer: A systematic analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17740-e17740.	0.8	1
65	The use of overnight pulse wave analysis for recognition of cardiovascular risk factors and risk. <i>Journal of Hypertension</i> , 2014, 32, 276-285.	0.3	16
66	The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. <i>International Journal of Cancer</i> , 2014, 134, 2314-2321.	2.3	24
67	QVA149 Improves Lung Function and Reduces Exacerbations Compared With Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study. <i>Chest</i> , 2014, 145, 410A.	0.4	1
68	Dual Bronchodilation With Once-Daily QVA149 Reduces Exacerbations, Improves Lung Function and Health Status Versus Glycopyrronium and Tiotropium in Severe-to-Very Severe COPD Patients: The SPARK Study. <i>Chest</i> , 2014, 145, 406A.	0.4	2
69	Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study. <i>Chest</i> , 2014, 145, 427A.	0.4	2
70	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. <i>British Journal of Cancer</i> , 2013, 109, 1821-1828.	2.9	118
71	Bronchodilatateurs dans la BPCO : quoi de neuf ? . <i>Revue Des Maladies Respiratoires Actualites</i> , 2013, 5, 619-621.	0.0	0
72	Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. <i>Lancet Respiratory Medicine</i> , the, 2013, 1, 199-209.	5.2	456

#	ARTICLE	IF	CITATIONS
73	QVA149 versus glycopyrronium for COPD – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2013, 1, e23.	5.2	1
74	Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. <i>International Journal of Cancer</i> , 2013, 133, 1825-1831.	2.3	20
75	Radiological and clinical outcomes of using Chartis® to plan endobronchial valve treatment. <i>European Respiratory Journal</i> , 2013, 41, 302-308.	3.1	221
76	Editorial: Entwicklungen in der Bronchoskopie: –Bronchoskopie 2.0–. <i>Atemwegs- Und Lungenkrankheiten</i> , 2013, 39, 157-158.	0.0	0
77	Bronchoskopische Lungenvolumenreduktion. <i>Atemwegs- Und Lungenkrankheiten</i> , 2013, 39, 224-237.	0.0	0
78	Infected Mediastinal Bronchogenic Cyst in a 12 Year Old Girl. <i>Thoracic and Cardiovascular Surgeon</i> , 2012, 60, 239-241.	0.4	1
79	Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. <i>European Respiratory Journal</i> , 2012, 39, 1334-1342.	3.1	281
80	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. <i>Pneumologie</i> , 2011, 65, 39-59.	0.1	133
81	Closure of persisting air leaks in patients with severe pleural empyema – use of endoscopic one-way endobronchial valve –. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 401-403.	0.6	29
82	Influence of expression of estrogen (ERS-1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 7585-7585.	0.8	2
83	Adherence to Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea: Impact of Patient Education after a Longer Treatment Period. <i>Respiration</i> , 2010, 80, 32-37.	1.2	29
84	A Randomized Study of Endobronchial Valves for Advanced Emphysema. <i>New England Journal of Medicine</i> , 2010, 363, 1233-1244.	13.9	704
85	Sleep-disordered breathing and type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2008, 81, 2-12.	1.1	276
86	Arthropathy and cutaneous manifestations in a 28-year-old patient with cystic fibrosis. <i>Monaldi Archives for Chest Disease</i> , 2006, 65, 114-5.	0.3	3
87	Inverse Correlation of Maturity and Antibacterial Activity in Human Dendritic Cells. <i>Journal of Immunology</i> , 2005, 174, 4203-4209.	0.4	52
88	Continuous Positive Airway Pressure Treatment Rapidly Improves Insulin Sensitivity in Patients with Obstructive Sleep Apnea Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 156-162.	2.5	525
89	The Effect of Continuous Positive Airway Pressure Treatment on Insulin Sensitivity in Patients with Obstructive Sleep Apnoea Syndrome and Type 2 Diabetes. <i>Respiration</i> , 2004, 71, 252-259.	1.2	198
90	Adiponectin in Patients with Obstructive Sleep Apnea Syndrome: Course and Physiological Relevance. <i>Respiration</i> , 2004, 71, 580-586.	1.2	57

#	ARTICLE	IF	CITATIONS
91	Resistin levels in patients with obstructive sleep apnoea syndrome--the link to subclinical inflammation?. <i>Medical Science Monitor</i> , 2004, 10, CR510-5.	0.5	49
92	Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. <i>European Respiratory Journal</i> , 2003, 22, 251-257.	3.1	241
93	Auto-CPAP therapy based on the forced oscillation technique. Auto-CPAP-Therapie auf der Basis der Oszilloresistometrie. <i>Biomedizinische Technik</i> , 2003, 48, 68-72.	0.9	13
94	Launois-Bensaude syndrome in a female with type 2 diabetes. <i>Medical Science Monitor</i> , 2003, 9, CS5-8.	0.5	5
95	Initiation of CPAP Therapy for OSA: Does Prophylactic Humidification during CPAP Pressure Titration Improve Initial Patient Acceptance and Comfort?. <i>Respiration</i> , 2002, 69, 406-412.	1.2	40
96	Unilateral anhidrosis of the leg. <i>Lancet, The</i> , 2002, 360, 129.	6.3	4
97	Auto-CPAP Therapy for Obstructive Sleep Apnea: Induction of Microarousals by Automatic Variations of CPAP Pressure?. <i>Sleep</i> , 2002, 25, 512-516.	0.6	28
98	Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. <i>Journal of Internal Medicine</i> , 2002, 252, 352-360.	2.7	49
99	Insulin Resistance, Hyperleptinemia, and Obstructive Sleep Apnea in Launois-Bensaude Syndrome. <i>Obesity</i> , 2002, 10, 625-632.	4.0	16
100	Sensitivity of a simplified forced oscillation technique for detection of upper airway obstruction. <i>Respiration Physiology</i> , 2001, 124, 243-249.	2.8	10
101	In vivo Efficacy of Two Heated Humidifiers Used During CPAP-therapy for Obstructive Sleep Apnea Under Various Environmental Conditions. <i>Sleep</i> , 2001, 24, 435-440.	0.6	16
102	Evaluation of a Portable Recording Device (Somnocheck <sup>®</sup> ) for Use in Patients with Suspected Obstructive Sleep Apnoea. <i>Respiration</i> , 2001, 68, 307-312.	1.2	44
103	Reproducibility of a Standardized Titration Procedure for the Initiation of Continuous Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnoea. <i>Respiration</i> , 2001, 68, 145-150.	1.2	19
104	Arousals: Aktueller Stand, Klinische Bedeutung und offene Fragen. Arousals: Actual Situation, Clinical Importance and Open Questions. <i>Somnologie</i> , 2001, 5, 24-45.	0.9	9
105	Inhalable Insulin: The Breakthrough in Insulin Therapy?. <i>Annals of Saudi Medicine</i> , 2001, 21, 45-48.	0.5	1
106	Disseminated manifestation of Kaposi's Sarcoma in newly diagnosed AIDS in an african female. <i>Medical Science Monitor</i> , 2001, 7, 1303-6.	0.5	0
107	An auto-continuous positive airway pressure device controlled exclusively by the forced oscillation technique. <i>European Respiratory Journal</i> , 2000, 16, 914-920.	3.1	33
108	Humidification During Continuous Positive Airway Pressure Therapy. <i>Chest</i> , 2000, 117, 925.	0.4	4

#	ARTICLE	IF	CITATIONS
109	VALIDITÄT DES RESPIRATORISCHEN IMPEDANZSIGNALS HINSICHTLICH DER DETEKTION VON RESPIRATORISCHEN MUSTERN ZUR STEUERUNG EINER AUTO-CPAP-THERAPIE BEIM OBSTRUKTIVEN SCHLAFAPNOE-SY.. Biomedizinische Technik, 2000, 45, 442.	0.9	0
110	In vivo efficacy of heated and non-heated humidifiers during nasal continuous positive airway pressure (nCPAP)-therapy for obstructive sleep apnoea. Respiratory Medicine, 2000, 94, 364-368.	1.3	21
111	Detection of obstructive sleep apnea by analysis of phase angle using the forced oscillation signal. Respiration Physiology, 2000, 123, 87-99.	2.8	10
112	Das erste oszilloresistometrisch gesteuerte auto-CPAP-Gerät (Somnosmart Â®)â€”Eine Therapie des lageabhÃngigen Schlafapnoe-Syndroms?. Somnologie, 1999, 3, 328-334.	0.9	1
113	A heated humidifier reduces upper airway dryness during continuous positive airway pressure therapy. Respiratory Medicine, 1999, 93, 21-26.	1.3	55
114	Are Snoring Medical Students at Risk of Failing their Exams?. Sleep, 1999, 22, 205-209.	0.6	25
115	Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS. Infection, 1998, 26, 368-374.	2.3	4
116	Evaluation of an auto-CPAP device for treatment of obstructive sleep apnoea. Thorax, 1998, 53, 643-648.	2.7	55
117	Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. European Respiratory Journal, 1998, 11, 14-19.	3.1	112